AGIO
Agios Pharmaceuticals, Inc. [AGIO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AGIO Stock Summary
In the News
AGIO Financial details
Company Rating
-
Market Cap
1.64B
Income
-342.49M
Revenue
26.82M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
389
Optionable
No
Shortable
Yes
Earnings
18 Oct 2023
P/E
-24.08
Forward P/E
-
PEG
-0.68
P/S
66.21
P/B
1.38
P/C
-
P/FCF
-4.45
Quick Ratio
12.78
Current Ratio
13.73
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-6.16
EPS next Y
-
EPS next Q
-
EPS this Y
365.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-0.86%
Revenue last 5Y
-25.63%
Revenue Q/Q
-4%
EPS Q/Q
4.88%
-
-
-
-
SMA20
0.09%
SMA50
-42.21%
SMA100
-27.99%
Inst Own
-
Inst Trans
-
ROA
-5%
ROE
-5%
ROC
-0.36%
Gross Margin
87%
Oper. Margin
-1859%
Profit Margin
-275%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
19.8-35.5
52W High
+0.63%
52W Low
+85.37%
RSI
54.02
Rel Volume
1.25
Avg Volume
817.19K
Volume
1.02M
Perf Week
7.84%
Perf Month
0.28%
Perf Quarter
-22.35%
Perf Half Y
-25.22%
-
-
-
-
Beta
0.952892
-
-
Volatility
0.72%, 0.85%
Prev Close
4.36%
Price
35.22
Change
3.59%
Company Profile
- Volume Average 817.19K
- Market Capitalization 1.64B
- Employee 389
- CEO Mr. Brian M. Goff M.B.A.
- Headquarters Cambridge,MA,US
- IPO Date 2013-07-24
-
Website
https://www.agios.com 
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
